ClinicalTrials.gov
Cure8 trial brief
Why This Matters
People with Crohn’s disease often have disrupted gut microbiomes; this trial tests a food-based approach (cranberry powder) that could potentially encourage beneficial bacteria and reduce inflammation, which is of direct interest to people seeking diet-related strategies.
Who Should Pay Attention
Adults with Crohn’s disease, caregivers interested in dietary interventions, clinicians advising patients about supplements, and researchers studying the gut microbiome and diet-based therapies.
Study Snapshot
Story typeClinical Reference
Trial phaseEarly Phase 1
Enrollment50 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This trial is exploring whether a cranberry-based supplement can shift the gut microbiome and markers of inflammation and quality of life in adults with Crohn’s disease. It uses home collection kits for stool, urine, and capillary blood and applies metagenomic sequencing to measure species-level changes.
The study is small (planned N=50) and early-phase, focused on biological and feasibility outcomes rather than proving clinical benefit. Participants are randomized and blinded to cranberry versus a matched placebo for 10 weeks, with a 4-week follow-up.
If you’re considering joining, note the trial’s specific eligibility (ages 18–65) and that it tracks daily adverse events and medication changes; it does not by itself establish that cranberry supplements improve symptoms or disease course.
Keep In Mind
This is an early-phase, small randomized trial focused on microbiome and biomarker changes rather than definitive clinical outcomes. Results from phase 1 trials are preliminary and intended to inform later, larger studies. The record describes planned methods and outcomes; it does not report results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorAna Maldonado-Contreras
Trial IDNCT07170462
Study typeInterventional
Trial phaseEarly Phase 1
Enrollment50 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 20, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Study explores microbiome reboot to prolong effect of Crohn's disease therapy
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in...
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective,...
Faecalibacterium prausnitzii Trial for Crohn's Disease Remission - Bioengineer.org
This study tests a live Faecalibacterium prausnitzii probiotic (EXL01) as a way to prolong steroid-induced remission in Crohn’s disease, a potential new strategy to reduce relapses and steroid exposure.